AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RECURSION PHARMACEUTICALS, INC. Director's Dealing 2026

Feb 10, 2026

31628_dirs_2026-02-10_294dcb93-4baa-4907-91ce-922ffab06639.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK: 0001601830
Period of Report: 2026-02-06

Reporting Person: Khan Najat (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-06	Class A Common Stock	A	1673546	—	Acquired	2284681	Direct
2026-02-06	Class A Common Stock	A	30346	—	Acquired	2315027	Direct
2026-02-06	Class A Common Stock	F	10364	$3.98	Disposed	2304663	Direct

Footnotes

F1: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter.

F2: This RSU vested immediately upon the grant date.

F3: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.